Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults

JAMA Internal Medicine

Volumn 178, Issue 2, 2018, Pages 248-258

  Le, Phuc ^a   Rothberg, Michael B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUBUNIT VACCINE; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKOV CHAIN; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; VACCINATION; VERY ELDERLY; AGE; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HERPES ZOSTER; IMMUNOLOGY; VARICELLA ZOSTER VIRUS;

AGE FACTORS; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; VACCINATION;

EID: 85041104944     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2017.7431     Document Type: Article

References (37)

1. Morrison VA, Johnson GR, Schmader KE, et al; Shingles Prevention Study Group. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900-909.
2. Oxman MN, Levin MJ, Johnson GR, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
3. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922-928.
4. Schmader KE, Oxman MN, Levin MJ, et al; Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis. 2012;55(10):1320-1328.
5. Lal H, Cunningham AL, Godeaux O, et al; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096.
6. Leidner AJ. Overview of two economic models that assess the cost-effectiveness of herpes zoster vaccinations. https://www. cdc. gov/vaccines/acip/meetings/downloads/slides-2017-06/zoster-04-leidner. pdf. Published June 21, 2017. Accessed July 14, 2017.
7. Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7):489-497.
8. Le P, Rothberg MB. Determining the optimal vaccination schedule for herpes zoster: a cost-effectiveness analysis. J Gen Intern Med. 2017;32(2):159-167.
9. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44(10):1280-1288.
10. Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers: medical care. http://Data. bls. gov/cgi-bin/surveymost. Accessed November 20, 2014.
11. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748-753.
12. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 2011;52(3):332-340.
13. Jackson LA, Reynolds MA, Harpaz R. Hospitalizations to treat herpes zoster in older adults: causes and validated rates. Clin Infect Dis. 2008;47(6):754-759.
14. National Center for Health Statistics, Centers for Disease Control and Prevention. Compressed mortality file 1999-2012 on CDCWONDER online database, released October 2014. Data are from the compressed mortality file 1999-2012 Series 20 No. 2R, 2014, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. http://Wonder. cdc. gov/cmf-icd10. html. Accessed November 12, 2014.
15. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145 (5):317-325.
16. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP). https://www. ahrq. gov/research/data/hcup/index. html. Page last reviewed November 2017. Accessed April 30, 2016.
17. Rohan P. FDA clinical briefing document for Merck & Co, Inc: zoster vaccine live (Oka/Merck): Zostavax. https://www. fda. gov/OHRMS/DOCKETS/ac/05/briefing/5-4198B2-1. pdf. Vaccines and Related Biological Products Advisory Committee meeting date December 15, 2005. Accessed October 30, 2014.
18. Cunningham AL, Lal H, KovacM, et al; ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019-1032.
19. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a Vaccine Safety Datalink study. Am J Public Health. 2009;99(suppl 2):S389-S397.
20. EdmundsWJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19(23-24):3076-3090.
21. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory. J Pain. 2004;5(6):344-356.
22. DroletM, Levin MJ, Schmader KE, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012;30(12): 2047-2050.
23. Bureau of Labor Statistics. Usual weekly earnings of wage and salary workers archived news releases: 2014 usual weekly earnings of wage and salary workers: fourth quarter. https://www. bls. gov/bls/news-release/wkyeng. htm. Accessed March 27, 2015.
24. Centers for Disease Control and Prevention. Adult vaccine price list. http://Www. cdc. gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. Prices last reviewed/updated September 1, 2017. Accessed September 12, 2014.
25. Centers for Medicare & Medicaid Services. Physician fee schedule search tool. http://Www. cms. gov/apps/physician-fee-schedule/search/search-results. aspx?Y=0&T=0&HT=0&CT =3&H1=90471&M=5. Accessed September 12, 2014.
26. Bouhassira D, Chassany O, Gaillat J, et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain. 2012;153(2):342-349.
27. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000;321 (7264):794-796.
28. Yawn BP,Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011;86 (2):88-93.
29. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26 (4):391-400.
30. Prosser LA, O'Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics. 2008;26(2):163-178.
31. Whitney CG, Zhou F, Singleton J, Schuchat A; Centers for Disease Control and Prevention (CDC). Benefits from immunization during the Vaccines for Children program era: United States, 1994-2013. MMWRMorb Mortal Wkly Rep. 2014;63(16):352-355.
32. Zhou F, Bisgard KM, Yusuf HR, Deuson RR, Bath SK, Murphy TV. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics. 2002;110(4):653-661.
33. Singhal PK, Makin C, Pellissier J, Sy L, White R, Saddier P. Work and productivity loss related to herpes zoster. J Med Econ. 2011;14(5):639-645.
34. Bureau of Labor Statistics. May 2016 national occupational employment and wage estimates: United States. http://Www. bls. gov/oes/current/oes -nat. htm. Last modified date March 31, 2017. Accessed July 10, 2017.
35. Bureau of Labor Statistics. Labor force statistics from the Current Population Survey: employment status of the civilian noninstitutional population by age, sex, and race. http://www. bls. gov/web/empsit/cpseea13. htm. Updated 2015. Accessed February 11, 2015.
36. Dooling K. Considerations for the use of herpes zoster vaccines. https://www. cdc. gov/vaccines/acip/meetings/downloads/slides-2017-06/zoster-05-dooling. pdf. Presented June 21, 2017. Accessed July 14, 2017.
37. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWRRecomm Rep. 2008;57(RR-5):1-30.